UPDATES: 3 Magic Valley football teams battle in state championships
Cameron Williams, No. 33, finishes at the rim over the defense as teammate Xavier Hall, No. 20, watches, anticipating a rebound attempt. Brandt Young|Sampson Independent Dontavious Smith, No. 12, finishes the play through contact while Cameron Williams, No. 33, crashes the boards. Brandt Young|Sampson Independent Nakai Owens brings the ball up the court for the Leopards. Brandt Young|Sampson Independent Xavier Hall, No. 20, swats an early shot attempt from the Devil Pups away over top a crowd of teammates and opponents. Brandt Young|Sampson Independent Lakewood boys’ basketball team hosted their first home game of the season Friday night, after going 2-1 through their first three games on the road this season. The visiting Lejeune Devil Pups looked to take down the Leopards, but it was Lakewood’s game through most of it, as the Leopards took the 69-60 victory. The teams came out battling defensively, and not a point was scored through the first minute. The scoring opened with a three-pointer by Lejeune with 6:47 to go in the first quarter. Lakewood’s first points came on a Dontavius Smith triple, assisted by Dashaun Carr shortly after the opening three from the Devil Pups, tying the game at 3. Carr doubled up on the assists when he sent a rocket of a pass deep in the key to Cameron Williams, who tossed up the layup and gave Lakewood their first lead of the night at 5-3. The Leopard defense started giving the Pups fits early, as the lengthy duo of Xavier Hall and Cameron Williams shut down the paint while Carr, Smith, and Nakai Owens filled out the guards and forwards positions. Lakewood had the slim 7-6 advantage before a Hall defensive rebound led to Carr handing him an assist at the other end on a fingertip layup for the big man, which opened the lead up to 9-6 with 3:03 to go in the first period. Jaziah Brunson went for a floater through the lane before quickly passing it to Owens, who sank a baseline jumper and gave them the 11-6 lead, forcing a Lejeune timeout with 2:40 to play in the opening quarter. Carr pickpocketed a steal and took it to the other end for a score after the break, and a Williams block sent Brunson to the other end on a breakaway layup, which he sank, but was fouled on. He hit the ensuing free throw, and Lakewood had the 16-6 lead with under two minutes to play. The Devil Pups made a run at the end of the quarter, tightening the score back at 16-13 before Williams sank a long jumper to stop the run. Lejeune responded with a deep three at the end of the quarter, making it an 18-16 lead for Lakewood on the heels of a 10-2 run by the Pups to end the opening period. Brunson made Lakewood’s first basket of the second quarter when he went 2-for-2 on free throws with just under seven minutes to play. Two more baskets went through for the home team, and they started a run of their own with the 22-16 lead in the second quarter. Williams hit back-to-back jumpers from the left elbow and propelled his team to the 26-16 lead with 5:13 left in the second quarter before they forced another Lejeune timeout. The Devil Pups were able to stop the bleed a bit, but not much, as the score moved to 29-19 with three minutes left in the half. A Hall block led to him being assisted another layup at the other end, and Lakewood moved to a 31-19 lead. Things were clicking for the Leopards all around, with a stifling defense, rebounding skills that couldn’t be matched, and nearly every shot falling for them. They held the 34-24 advantage at halftime. Scoring in the second half was opened again by Hall, who hit a put-back layup in the low key to give the Leopards the 36-24 lead. He added two more on a similar play a minute later. Things continued moving in Lakewood’s favor when Smith hit a floater up the middle, Williams finished a drive with a turn around jumper in the low block, and Brunson took a fast break for an easy score. Quickly the Leopards moved to a 44-26 lead with 3:59 to play in the third. Since the Pups’ 10-2 run to close out the first quarter, they were outscored 28-10 to this point. As the clock showed 1:48 left in the third, the score stood at 46-32, with Lakewood in full control. While they had the lead, the Leopards still found themselves in serious foul trouble late in the quarter — they had tallied five after just six minutes of play. A deep layup by Williams stretched the lead out to 48-34 with under half a minute to go in the period. Scoring opened for both teams in the fourth quarter. With under five minutes to go in the game, Lakewood jumped out to a 57-44 advantage on plays from Hall, Williams, and company. Williams sent another basket home on a drive down the baseline, giving them the 59-46 lead before the Devil Pups took the ball down the court and returned the favor. The points kept falling for the Leopards, but the Devil Pups made a valiant attempt at comeback. It was too-little-too-late though, and Lakewood took the 69-60 victory in front of their hometown crowd. “It feels really good,” Leopard head coach Brandon Powell said after the game. “The guys are really growing. They’re starting to get a little bit of cohesiveness and work together better. Communication is a little better, which is why the defense is better tonight.” The Leopards moved to 3-1 on the season. They will host East Columbus on Thursday in the Chasity Melvin Holiday Tournament. Tipoff for that game will be 8 p.m. Reach Brandt Young at (910) 247-9036, at byoung@clintonnc.com, or on the Sampson Independent Facebook page.Susan Shelley: We’re all-in to Make America Healthy Again
Arclin unveils striking new brand that stands out in the material science industry with exacting precision and a bold new look
Games on a college basketball schedule don't contrast much more than the two NC State has this week. The Wolfpack (6-3) host Coppin State (0-10) on Tuesday in Raleigh, N.C., then hit the road to challenge No. 10 Kansas on Saturday. NC State enters its unusual week after snapping a three-game skid with an 84-74 overtime win at home Saturday against Florida State in its Atlantic Coast Conference opener. Transfers Marcus Hill and Dontrez Styles each had their season high, scoring 23 and 21 points, respectively. They scored 13 of NC State's 14 points in overtime. "Dontrez Styles was tremendous," Wolfpack coach Kevin Keatts said. "In the second half, he made play after play." Hill, who was the top scorer last year at Bowling Green (20.5 points per game), and Styles, who was the second-leading scorer last year at Georgetown (12.8 ppg), combined to hit 14 of 25 shots and pull down 11 rebounds. The win followed defeats to then-No. 13 Purdue and BYU, both by double-digit margins, in the Rady Children's Invitational and a 63-59 loss to Texas in the SEC/ACC Challenge. "The little things that impact the game are defending, making free throws and blocking out," Keatts said. "We handled that much better than we did against Texas." Coppin State arrives in Raleigh on a 23-game losing streak dating to January -- the longest current run of futility in Division I. Each of the Eagles' losses this season have come by double-digit margins, though they have been more competitive lately, falling to Baltimore rival Loyola (Md.) 68-57 and at Wagner 65-52 last week. Julius Ellerbe III has been one of Coppin's most reliable players lately, scoring a combined 20 points in the last two games. He had 16 points and 12 rebounds in a loss to George Mason last month. Teammate Peter Oduro recorded a double-double, with 16 points and 10 rebounds, in last month's loss at Saint Joseph's. "These things take time," Coppin State second-year coach Larry Stewart said. "It takes time to establish your culture. It takes time to get the right players in your system." --Field Level Media
Search for Missing 17-Year-Old Sophia Cano Continues in North Bexar County, San Antonio Police Request Public AssistanceCorcept Therapeutics' chief accounting officer sells $80,031 in stockVANCOUVER — A family of killer whales has made a rare trip into waters off downtown Vancouver for what an expert says was likely a "grocery shopping" hunt for harbour seals. Video shared on social media by False Creek Ferries shows the whales cruising past highrise towers at the entrance to False Creek on Sunday. Andrew Trites, director of the University of British Columbia's marine mammal research unit, has identified the whales as a family group of transient orcas consisting of a mother and her three offspring. He says it's the first time the 26-year-old mother, known as T35A, has shown up in downtown Vancouver with her offspring aged six, 11 and 14. Trites says the well documented family has previously been seen by marine researchers from Alaska to the Juan de Fuca Strait south of Vancouver Island. He attributes the pod's surprising downtown appearance to seals also changing their habits as they hide from orcas, forcing killer whales to hunt in backwater areas like False Creek. Trites says the video shows the whales moving quietly like "ghosts" to avoid alerting their prey. Killer whales have previously been spotted in False Creek, including in 2019, and in 2010 a grey whale swam all the way to the end of the inlet, near Science World. This report by The Canadian Press was first published Nov. 25, 2024. Nono Shen, The Canadian Press
Portugal winger Nani announces retirementThree-game skid over, NC State faces winless Coppin StateMeghan Markle speaks out after professional 'separation' from Prince HarryThe Transportation Security Administration has some reminders for those heading to airports during the holidays. “People seem to forget some of the more common and routine steps that they need to take when packing for a flight or when they are going through a checkpoint, perhaps because they’re focused on being at their destination and not focusing on what needs to happen before getting there,” said TSA officer Christopher Kirchein of John F. Kennedy International Airport. “Travelers sometimes ignore the advice that we give them,” said TeaNeisha Barker, a TSA uniformed adviser. “We are providing guidance so that they get through the checkpoint as simply and conveniently as possible. Not every airport has the same technology, so listen to the guidance we are offering.” “Passengers forget that knives and other weapons are not allowed through our checkpoints. It’s shocking to see so many people with knives,” said TSA officer Aisha Hicks of Philadelphia International Airport. “Weapons of any kind are prohibited through a TSA checkpoint.” TSA officers shared this list of the common things that travelers forget and should remember when coming to a security checkpoint. Ten things that travelers need to remember when preparing to go through the security screening process: • Remember that you cannot bring bottles of water, energy drinks, juice, coffee, soda or any filled insulated reusable container through a security checkpoint. However, they can finish their beverage and bring the empty bottle or container with them. • Remember to bring your ID to the checkpoint. • Remember when TSA officers remind you to remove everything from your pockets that it does not only mean metallic items such as keys and mobile phones, but it means everything, including non-metallic items such as tissues, lip balm, breath mints, etc. • Remember that you cannot bring a firearm through a checkpoint. Instead, pack your unloaded firearm in a locked hard-sided case and declare it at your airline check-in counter and the airline will ensure it is transported in the belly of the plane where nobody has access to it. • Remember that you need to remove your shoes when getting screened and then end up barefoot on the floor. It’s probably a good idea to wear socks. • Remember that children 12 and under are allowed to travel through a TSA PreCheck screening lane with a parent who has TSA PreCheck on their boarding pass. In addition, don’t forget that children up to the age of 18 can also come into the TSA PreCheck lane with their parent if they are on the same airline reservation as their parent. • Remember that passengers that appear 12 and under or 75 and older do not need to remove their shoes and light jacket. • Remember, if you are putting a lock on your luggage, make sure it is a TSA compatible lock so that if TSA officers need to open your luggage, they can unlock it and relock it. If the lock is not TSA compliant, TSA officers who need to open your luggage will cut off the lock, rendering it useless. • Remember that you can bring medications through a security checkpoint, even liquid medication. Just let the TSA officer know that you have liquid medication with you so it can be screened separately. • Remember to get a REAL ID-compliant driver’s license sooner rather than later because REAL ID goes into effect on May 7.
Three-game skid over, NC State faces winless Coppin State
C$ unless otherwise stated TSX/NYSE/PSE: MFC SEHK: 945 TORONTO , Dec. 9, 2024 /PRNewswire/ - Manulife has been notified of an unsolicited mini-tender offer made by New York Stock and Bond LLC (New York Stock and Bond) to purchase up to 50,000 Manulife common shares, or less than 0.003% of the common shares outstanding, at a price of USD$12.50 per share. Manulife is in no way associated with New York Stock and Bond and does not recommend or endorse acceptance of this unsolicited offer. Manulife cautions shareholders that the mini-tender offer has been made at a price below the current market price for Manulife shares. The offer represents a discount of approximately 60.76% and 60.80%, respectively, below the closing prices of Manulife common shares on the TSX and NYSE on November 27, 2024 , the last trading day before the mini-tender offer was commenced, and a discount of 61.43% and 61.42%, respectively, below the closing prices on the TSX and NYSE on December 6, 2024 . Mini-tender offers are designed to seek less than 5% of a company's outstanding shares, avoiding disclosure and procedural requirements applicable to most bids under Canadian and U.S. securities regulations. The Canadian Securities Administrators (CSA) and the U.S. Securities and Exchange Commission (SEC) have expressed serious concerns about mini-tender offers, including the possibility that investors might tender to such offers without understanding the offer price relative to the actual market price of their securities. The SEC states that "bidders make mini-tender offers at below-market prices, hoping that they will catch investors off guard if the investors do not compare the offer price to the current market price." Shareholders should carefully review the New York Stock and Bond offer documents and current market price for Manulife shares, and consult their investment advisors regarding any offer they may receive and review with their advisors all options for their investment in Manulife shares. Manulife has stock transfer agents providing shareholder services in Canada , the United States , Hong Kong and the Philippines . These local agents provide services directly to our registered shareholders and can provide information on share account management, direct deposit of dividends, dividend reinvestment and share purchase plans. Please email manulifeinquiries@tmx.com for more information. Manulife requests that a copy of this news release be included in any distribution of materials relating to New York Stock and Bond's mini-tender offer for Manulife common shares. About Manulife Manulife Financial Corporation is a leading international financial services provider, helping people make their decisions easier and lives better. With our global headquarters in Toronto, Canada , we provide financial advice and insurance, operating as Manulife across Canada , Asia , and Europe , and primarily as John Hancock in the United States . Through Manulife Investment Management, the global brand for our Global Wealth and Asset Management segment, we serve individuals, institutions, and retirement plan members worldwide. At the end of 2023, we had more than 38,000 employees, over 98,000 agents, and thousands of distribution partners, serving over 35 million customers. We trade as 'MFC' on the Toronto , New York , and the Philippine stock exchanges, and under '945' in Hong Kong. Not all offerings are available in all jurisdictions. For additional information, please visit manulife.com . View original content to download multimedia: https://www.prnewswire.com/news-releases/manulife-cautions-investors-regarding-new-york-stock-and-bond-llc-offer-for-shares-302326646.html SOURCE Manulife Financial Corporation
Ex Napoli Star Not Hiding Inter Milan Ambitions After Going Top Of Champions League: ‘We Want To Go All The Way In All Competitions’DAYTONA BEACH, Fla. (AP) — Ian Schieffelin had 18 points, 13 rebounds and eight assists in leading Clemson to a 75-67 win over Penn State on Tuesday and the championship of the Sunshine Slam Beach Division. Chase Hunter added 17 points, Chauncey Wiggins 14 and Del Jones 10 for the Tigers (6-1), who shot 44% and made 9 of 19 3-pointers led by Hunter's three. Ace Baldwin Jr. scored 20 points and had 11 assists, Yanic Konan Niederhauser added 14 points and Nick Kern Jr. 11 for the Nittany Lions (6-1), who shot 46% and were just 4 of 18 from the arc. Neither team had a double-digit lead in the game and it was tied with seven minutes to go. But Penn State had a six-minute drought without a field goal while committing three turnovers and the Tigers went up by six. A hook shot from Schieffelin with a minute to go made it a five-point lead and free throws sealed it from there. The eight-point final margin was the largest of the game. Konan Niederhauser's dunk to open the second half tied the game but a Hunter 3-pointer gave the lead back to Clemson. Penn State took its first lead of the second half on a 9-0 run, seven coming from Baldwin, to go up 57-54 with midway through the period. Penn State had its largest lead of seven in the first half but three consecutive 3s put Clemson ahead with three minutes to go and the Tigers led at 38-36 at halftime. Clemson had a 16-9 edge on points off turnovers. ___ Get poll alerts and updates on the AP Top 25 throughout the season. Sign up . AP college basketball: andOpenAI launches Sora AI video generator for public
All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile First Patient to Reach 6-Month Follow-up Remains in DORIS Clinical Remission and Free of All Immunosuppressive Therapies Company Plans to Initiate Dose Expansion at First Dose Level of 360M Cells SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today presented new clinical and translational data from the Company's FT819 Phase 1 Autoimmunity study for moderate-to-severe systemic lupus erythematosus (SLE) at the American Society of Hematology (ASH) Annual Meeting being held in San Diego, CA. The first three study patients, each of whom presented with active lupus nephritis (LN) despite having been treated with multiple standard-of-care therapies, received fludarabine-free conditioning followed by a single dose of FT819 at 360 million cells. There were no dose-limiting toxicities (DLTs), no events of any grade of cytokine release syndrome (CRS), immune effector-cell associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GvHD), and rapid, deep, and sustained elimination of CD19+ B cells in the periphery was observed during the first month of treatment. FT819 is the Company's off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate comprised of CD8αβ+ T cells with a memory phenotype and high CXCR4 expression to promote tissue trafficking. "We continue to be very pleased with early clinical observations of fludarabine-free conditioning and FT819 off-the-shelf, CAR T-cell therapy in patients with moderate-to-severe SLE. The remarkable experience of the first patient treated in April is ongoing, as the patient remains on-study in drug-free clinical remission. In addition, the initial clinical and translational data from the two additional patients treated at the first dose level continue to support the potential for disease transformation,” said Bob Valamehr, President of Research and Development of Fate Therapeutics. "We are now initiating dose expansion at this first dose level to accelerate development, and are also escalating dose based on the favorable safety profile observed. In addition, I am pleased to announce that the first patient has now been treated with FT819 as an add-on to maintenance therapy without conditioning chemotherapy. We believe our therapeutic approach is highly-differentiated and has the potential to transform disease outcomes without requiring patient apheresis, discontinuation of maintenance therapy, intense conditioning chemotherapy, and extended hospitalization.” FT819 Phase 1 Autoimmunity Study The ongoing multi-center, Phase 1 clinical trial for patients with moderate-to-severe SLE is designed to evaluate the safety, pharmacokinetics, and anti-B cell activity of FT819 (NCT06308978). The first three patients, all of whom presented with active LN despite having been treated with multiple standard-of-care therapies, received fludarabine-free conditioning consisting of either cyclophosphamide alone or bendamustine alone, followed by a single dose of FT819 at 360 million cells. In all three patients, FT819 was detected in the peripheral blood and rapid, deep, and sustained elimination of CD19+ B cells in the periphery was observed during the first month of treatment. All three patients remain on-study, and there have been no DLTs and no events of any grade of CRS, ICANS, or GvHD. Based on these clinical observations, the Company is initiating dose expansion in up to 10 patients at this first dose level, and is also escalating dose to 720 million cells. The Company's FT819 Phase 1 Autoimmunity study also includes a second treatment arm to assess the safety, pharmacokinetics, and anti-B cell activity of a single dose of FT819 as an add-on to maintenance therapy without conditioning chemotherapy in patients with SLE. The first patient has now been treated in this second arm, which is being conducted in parallel with the study's conditioning arm. FT819 Patient 1 Case Study The first patient treated in the Phase 1 Autoimmunity study presented with active LN and severe disease, which was marked by renal BILAG A (British Isles Lupus Assessment Group) disease activity score based on biopsy, SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index) score of 20, FACIT-Fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue) score of 33 (range 0-52, where a score of 52 indicates no fatigue) and PGA (Physician Global Assessment) score of 2.5 (where a score of 3 indicates most severe activity). Following administration of fludarabine-free conditioning and treatment with a single dose of FT819 at 360 million cells, the patient was discharged from the hospital without notable adverse events (AEs) after a protocol-required three-day stay. Rapid elimination of CD19+ B cells in the periphery was observed following treatment, and B-cell recovery by Month 3 was predominantly comprised of naïve, non-class switched B cells with near-complete elimination of switched memory B cells and deep depletion of plasmablasts, indicative of an immune reset. The patient reported that her debilitating fatigue had entirely resolved without further treatment, and treatment with methylprednisolone was discontinued at Month 3. The patient achieved DORIS (definition of remission in SLE) clinical remission, including with resolution of arthritis and active urinary sediment and with a substantial reduction in proteinuria, as of Month 6 follow-up. The patient continues on-study, in DORIS clinical remission, and remains free of all immunosuppressive therapy. iPSC-derived CAR T-cell Product Platform The Company also highlighted the scientific progress of its proprietary iPSC-derived CAR T-cell product platform at the ASH Annual Meeting. In an oral presentation entitled " Off-the-shelf Product Candidate Incorporates Novel Sword & Shield Technology Designed to Promote Functional Persistence without Conditioning Chemotherapy ”, the Company compared its novel Sword & Shield technology, which utilizes a 4-1BB-targeted CAR (ADR) alongside the complete knock-out of CD58 (CD58KO) to both target and evade host alloreactive immune cells, to other host immune evasion strategies. In preclinical studies of allogeneic models, the Company showed that its Sword and Shield Technology specifically engaged with alloreactive T cells and supported functional persistence while avoiding the killing of general host T cells and activated anti-tumor T cells. This unique observation was not seen with other approaches that are either too broad and undesirably eliminate most of the host immune system or have limited coverage and cannot adequately protect the allogeneic cell product. In a second presentation entitled " Development of Induced Pluripotent Stem Cell-Derived T Cells Exhibiting Phenotypic and Functional Attributes of Primary CAR T Cells ”, the Company conducted a series of high-resolution analyses to show stimulated iPSC-derived T cells elicit primary T-cell like activation, proliferation, transcriptional and functional program engagement, and iPSC-derived CAR T cells uniquely emulate antigen-mediated response similar to primary-derived autologous CAR T cells. About Fate Therapeutics' iPSC Product Platform Human induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company's proprietary iPSC product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. Analogous to master cell lines used to mass produce biopharmaceutical drug products such as monoclonal antibodies, the Company utilizes its clonal master iPSC lines as a starting cell source to manufacture engineered cell products which are well-defined and uniform in composition, can be stored in inventory for off-the-shelf availability, can be combined and administered with other therapies, and can potentially reach a broad patient population. As a result, the Company's platform is uniquely designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Fate Therapeutics' iPSC product platform is supported by an intellectual property portfolio of over 500 issued patents and 500 pending patent applications. About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company's pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com . Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the safety and therapeutic potential of the Company's iPSC-derived CAR T-cell product candidates, including FT819, the advancement of and plans related to the Company's product candidates, clinical studies and preclinical research and development programs, the Company's progress, plans and timelines for the clinical investigation of its product candidates, including the expected clinical development plans for FT819, the initiation and continuation of enrollment in the Company's clinical trials, the initiation of additional clinical trials and additional dose cohorts in ongoing clinical trials of the Company's product candidates, the timing and availability of data from the Company's clinical trials, the therapeutic and market potential of the Company's research and development programs and product candidates, the Company's clinical and product development strategy, and the Company's expectations regarding progress, plans, and timelines. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company's research and development programs and product candidates, including those product candidates in clinical investigation, may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company's product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the initiation and conduct of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company's product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company's ongoing and planned clinical trials, difficulties or delays in manufacturing or supplying the Company's product candidates for clinical testing, failure to demonstrate that a product candidate has the requisite safety, efficacy, or other attributes to warrant further development, and any adverse events or other negative results that may be observed during preclinical or clinical development), and the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company's periodic filings with the Securities and Exchange Commission, including but not limited to the Company's most recently filed periodic report, and from time to time in the Company's press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. Contact: Christina Tartaglia Precision AQ 212.362.1200 [email protected]
Dundee United are set to be boosted by the return of Louis Moult – the club’s “most natural finisher” – for Saturday’s testing trip to face Rangers. Moult, 31, has been absent since suffering a knock to the knee against Kilmarnock on September 28. The severity of the injury proved to be far worse than initially feared but, as reported by on Tuesday, the experienced frontman has been back in And boss Jim Goodwin has confirmed that Moult is set to be in contention for the clash at Ibrox, with the ex-Motherwell hero desperate to feature – even if that means playing through the pain barrier. “Moulty was unlucky,” reflected Goodwin. “After scoring a couple of goals, hitting form and getting his place in the team – for that (injury) to happen at Rugby Park was a major disappointment for him. “But he is back now. “There is still a little bit of discomfort, but his injury is different from the hamstring injuries to (Kristijan) Trapanovski and (Ross) Graham. “Moulty’s is more of an impact thing, so it’s more about whether you can play through the pain – and Moulty wants to do that.” Given he has been sidelined for close to two months, it would be a major shock to see Moult asked to produce anything more than a second half cameo. But given his pedigree and Goodwin reckons that could still be valuable if United are still in the game going into the final stages. “He is probably the most at the club,” continued Goodwin. “I see that every day in training. “Opportunities in front of goal might be limited on Saturday. . So, having someone like Louis available in the latter stages of the game could be important. “Hopefully, he’ll play a big part.” The game will come too soon for hamstring strain victims Kristijan Trapanovski and Ross Graham, with Goodwin adding: “Trapanovski came back from the muscle injury, and it happened again at Easter Road. “We don’t want a repeat of that with Ross Graham. We want everyone to be pain free when they come back – and be back for a long time.” Captain Ross Docherty suffered a slight setback as he seeks to reach peak fitness following a calf issue but is slated to take part in training on Friday. Goodwin is “hopeful” the midfielder will be in the squad against the Light Blues.Ousted Syrian leader Assad flees to Moscow after fall of Damascus, Russian state media say DAMASCUS, Syria (AP) — Russia media say ousted Syrian leader Bashar Assad has fled to Moscow and received asylum from his longtime ally. The reports came hours after a stunning rebel advance swept into Damascus to cheers and ended the Assad family’s 50 years of iron rule. Thousands of Syrians poured into streets echoing with celebratory gunfire, joyful after a stifling, nearly 14-year civil war. But the swiftly moving events raised questions about the future of the country and the wider region. The rebels face the daunting task of healing bitter divisions in a country still split among armed factions. One rebel commander said “we will not deal with people the way the Assad family did." Analysis: Collapse of Syria's Assad is a blow to Iran's 'Axis of Resistance' MANAMA, Bahrain (AP) — For Iran’s theocratic government, it keeps getting worse. Its decadeslong strategy of building an “Axis of Resistance” supporting militant groups and proxies around the region is falling apart. Hamas has been batttered by Israel's campaign in Gaza. In Lebanon, Israeli bombardment has crippled Iran’s most powerful ally, Hezbollah, even as Israel has launched successful airstrikes openly inside of Iran for the first time. And now Iran’s longtime stalwart ally and client in Syria, President Bashar Assad, is gone. Who is Abu Mohammed al-Golani, the leader of the insurgency that toppled Syria's Assad? BEIRUT (AP) — Abu Mohammed al-Golani, the militant leader who led the stunning insurgency that toppled Syria’s President Bashar Assad, has spent years working to remake his public image and that of his fighters. He renounced longtime ties to al-Qaida and depicts himself as a champion of pluralism and tolerance. The extent of that transformation from jihadi extremist to would-be state builder is now put to the test. The 42-year-old al-Golani is labeled a terrorist by the United States. He has not appeared publicly since Damascus fell early Sunday. But he and his insurgent force, Hayat Tahrir al-Sham, stand to be a major player in whatever comes next. Trump says he can't guarantee tariffs won't raise US prices and won't rule out revenge prosecutions WASHINGTON (AP) — Donald Trump says he can’t guarantee his promised tariffs on key U.S. foreign trade partners won’t raise prices for American consumers. And he's suggesting once more that some political rivals and federal officials who pursued legal cases against him should be imprisoned. The president-elect made the comments in a wide-ranging interview with NBC’s “Meet the Press” that aired Sunday. He also touched on monetary policy, immigration, abortion and health care, and U.S. involvement in Ukraine, Israel and elsewhere. Trump often mixed declarative statements with caveats, at one point cautioning “things do change.” The hunt for UnitedHealthcare CEO's elusive killer yields new evidence, but few answers NEW YORK (AP) — Police don’t know who he is, where he is, or why he did it. As the frustrating search for UnitedHealthcare CEO Brian Thompson’s killer got underway for a fifth day Sunday, investigators reckoned with a tantalizing contradiction: They have troves of evidence, but the shooter remains an enigma. One conclusion they are confident of, however: It was a targeted attack, not a random one. On Sunday morning, police declined to comment on the contents of a backpack found in Central Park that they believe was carried by the killer. Thompson was shot and killed Wednesday outside of a hotel in Manhattan. Trump calls for immediate ceasefire in Ukraine and says a US withdrawal from NATO is possible WASHINGTON (AP) — Donald Trump is pushing Russian leader Vladimir Putin to act to reach an immediate ceasefire with Ukraine. Trump describes it as part of his active efforts as president-elect to end the war despite being weeks from taking office. Trump also said he would be open to reducing military aid to Ukraine and pulling the United States out of NATO. Those are two threats that have alarmed Ukraine, NATO allies and many in the U.S. national security community. Ukrainian President Volodymyr Zelenskyy says any deal would have to pave the way to a lasting peace. The Kremlin's spokesman says Moscow is open to talks with Ukraine. Gaza health officials say latest Israeli airstrikes kill at least 14 including children DEIR AL BALAH, Gaza Strip (AP) — Palestinian health officials say Israeli airstrikes in central Gaza have killed at least 14 people including children, while the bombing of a hospital in northern Gaza has wounded a half-dozen patients. Israel’s military continues its latest offensive against Hamas militants in northern Gaza, whose remaining Palestinians have been almost completely cut off from the rest of the territory amid a growing humanitarian crisis. One airstrike flattened a residential building in the urban Bureij refugee camp Sunday afternoon. That's according to the Al-Aqsa Martyrs Hospital in the nearby city of Deir al-Balah, where the casualties were taken. South Korea's democracy held after a 6-hour power play. What does it say for democracies elsewhere? SEOUL, South Korea (AP) — A short-lived martial law decree by South Korea's leader last week raised worries about budding authoritarianism around the world. In the end, though, democracy prevailed. President Yoon Suk Yeol announced that he was declaring martial law and giving his government sweeping powers to crack down on protesters, ban political parties and control the media. Members of the military blocked lawmakers from using the legislature's constitutional power to cancel the power grab. But the National Assembly within hours unanimously voted to do so. Trump's return may be a boon for Netanyahu, but challenges abound in a changed Middle East TEL AVIV, Israel (AP) — Israeli Prime Minister Benjamin Netanyahu is jubilant about President-elect Donald Trump's return to the White House. Trump's first term policies skewed heavily in favor of Israel, and he has picked stalwart Israel supporters for key positions in his administration. But much has transpired since Trump left office in early 2021. The turmoil in the Middle East, the lofty ambitions of Netanyahu’s far-right governing coalition and Netanyahu’s own personal relationship with the president-elect could dampen that enthusiasm and complicate what on the surface looks like a seamless alliance. First 12-team College Football Playoff set, Oregon seeded No. 1 and SMU edges Alabama for last spot SMU captured the last open spot in the 12-team College Football Playoff, bumping Alabama to land in a bracket that placed undefeated Oregon at No. 1. The selection committee preferred the Mustangs (11-2), losers of a heartbreaker in the Atlantic Coast Conference title game, who had a far less difficult schedule than Alabama (9-3) of the SEC but one fewer loss. The first-of-its-kind 12-team bracket marks a new era for college football, though the Alabama-SMU debate made clear there is no perfect formula. The tournament starts Dec. 20-21 with four first-round games. It concludes Jan. 20 with the national title game in Atlanta.